Formulation and evaluation of sustained release pellets of lornoxicam

Objective: The aim of study was to develop sustained release pellets of lornoxicam using Eudragit RLPO and Eudragit RSPO to reduce the dosing frequency.

Methods: The sustained release pellets of lornoxicam were prepared by extrusion – spheronization technique using Eudragit RLPO and Eudragit RSPO as release retardant polymers and microcrystalline cellulose as spheronizing agent. A 32 Full factorial design was applied to investigate the combined effect of the two independent variables i.e. concentration of Eudragit RLPO (X1) and concentration of Eudragit RSPO (X2) on the dependent variables, In vitro drug release at 1h (Y1), In vitro drug release at 4h (Y2) and  In vitro drug release at 12 h. (Y3). 

Results: The optimized formulation (F0) show in vitro drug release 11.24 ± 1.21 %, 43.69 ± 1.28 %, 82.69 ± 1.74 % and 100.24 ± 1.56 %  at 1 h, 4 h, 12 h and 24 h respectively. Drug excipients compatibility study by FTIR showed no interaction between drug and excipients. Eudragit RLPO and Eudragit RSPO had significant effect on in vitro drug release.

Conclusion: From all parameter and experimental design evaluation, it was concluded that drug release rate decreased with an increase the concentration of Eudragit RLPO and Eudragit RSPO.  SEM Photomicrograph of pellets revealed that the surface was rough and the pellets were spherical shaped in nature. The in vitro release kinetics revealed higuchi model is followed and drug release is by anamolous diffusion.

Read the article here

More about microcrystalline cellulose

Article information: AMIN, M. J., PATEL, K. S., PATEL, D. R., PATEL, Z. P., & BAJAG, J. V. (2021). FORMULATION AND EVALUATION OF SUSTAINED RELEASE PELLETS OF LORNOXICAM: SUSTAINED RELEASE PELLETS OF LORNOXICAM. International Journal of Applied Pharmaceutics13(4). https://doi.org/10.22159/ijap.2021v13i4.41601

You might also like